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ABSTRACT  
Background 
HX575 (biosimilar epoetin alfa) was approved in Europe in 2007 for the treatment of chronic 
kidney disease (CKD)-related anemia. This study assessed clinical equivalence of HX575 with 
the US-licensed reference medicine (Epogen®/Procrit®, Amgen/Janssen) following 
subcutaneous (SC) administration in dialysis patients with anemia of CKD. 
Methods 
This was a randomized, double-blind, parallel-group, multicenter study (NCT01693029) 
conducted at 49 US clinical sites. Eligible patients were aged ≥18 years, had end-stage renal 
disease, were on hemodialysis or peritoneal dialysis for ≥6 months (or ≥12 months in the 
case of a failed kidney transplant), and were receiving treatment with stable SC doses of the 
reference medicine. Eligible patients also had mean hemoglobin (Hb) concentration 
between 9.0 and 11.5 g/dL during the screening period. The primary endpoint was the mean 
absolute change in Hb concentration between the screening/baseline period (week -4 to -1) 
and the evaluation period (week 21 to 28). 
Results 
Hb values at the end of the evaluation period and the Hb change from baseline to 
evaluation period were similar between treatment groups. The estimated difference 
between groups in mean absolute change in Hb concentration was -0.093 g/dL, with 90% CI 
(-0.23, 0.04) entirely within the pre-specified equivalence limits (-0.5, 0.5 g/dL). The safety 
profile of each medicine was similar and as expected in dialysis patients, and neither 
treatment led to the development of neutralizing, clinically relevant antibodies. 
Conclusions 
SC HX575 in dialysis patients with renal anemia was therapeutically equivalent to the 
reference medicine in terms of maintaining stable Hb levels.  
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INTRODUCTION 
HX575 (biosimilar epoetin alfa; Binocrit®, Hexal AG) was approved in Europe in 2007 for the 
treatment of chronic kidney disease (CKD)-related anemia. The initial approval of HX575 was 
for intravenous (IV) administration, which was in accordance with the label of the reference 
medicine at that time. More recently, a multinational, open-label, single-arm, phase III 
European study was conducted to evaluate the safety and immunogenicity of subcutaneous 
(SC) HX575 in CKD-related anemia in pre-dialysis and dialysis patients [Casadevall et al 
2017]. SC use of HX575 was found to be well tolerated and stable hemoglobin (Hb) levels 
were maintained. Based on these data, the SC administration of HX575 was approved by the 
European Commission in March 2016 [Binocrit® SmPC]. 
Here we report the results of a randomized, double-blind, efficacy and safety study (the 
ACCESS study, A Clinical Research Study in Chronic Kidney Disease & Anemia) conducted in 
the United States (US), which aimed to show clinical equivalence of HX575 with the US-
licensed reference medicine (Epogen®/Procrit®, Amgen/Janssen) following SC 
administration in dialysis patients with anemia of CKD. 
 
METHODS 
The study was a randomized, double-blind, parallel-group, multicenter study 
(NCT01693029) in which patients were enrolled at 49 US clinical sites. The relevant 
Institutional Review Boards approved the protocol and the trial was conducted in 
accordance with the Declaration of Helsinki International Council for Harmonisation (ICH) 
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Good Clinical Practice and any applicable local regulations. All analyzed patients provided 
written, informed consent.  
Male and female patients aged 18 years or older were eligible if they had end-stage renal 
disease and were on hemodialysis or peritoneal dialysis for at least 6 months (or at least 12 
months in the case of a failed kidney transplant). All patients had to be receiving treatment 
with stable (≤30% change in weekly dose during screening) SC doses of the reference 
medicine administered at least once per week, with a maximum weekly dose of 300 IU/kg. 
Eligible patients had mean Hb concentration between 9.0 and 11.5 g/dL during the 
screening period (samples were taken prior to the dialysis session, preferably in the middle 
of the week), and had adequate iron substitution (serum ferritin ≥200 μg/L and transferrin 
saturation ≥20%, confirmed by a sample taken at first screening). 
Main exclusion criteria included history of pure red cell aplasia (PRCA) or anti-erythropoietin 
antibodies; lack of efficacy or loss of effect with a previous erythropoiesis-stimulating agent 
(ESA) therapy; historical or current positive result for binding anti-erythropoietin antibodies. 
Eligibility was assessed during a 4-week screening period, after which patients entered a 52-
week treatment period. 
Study design 
Patients were randomized 1:1 by an interactive response technology to SC HX575 or 
reference medicine. During treatment, the dose was individually titrated to maintain Hb 
levels in the target range 10.0–11.0 g/dL. The primary endpoint was the mean absolute 
change in Hb concentration between the screening/baseline period (week -4 to -1) and the 
evaluation period (week 21 to 28). The primary analysis was performed in the intention to 
treat (ITT) population, which consisted of all randomized patients who were exposed to 
treatment with study drug for ≥4 weeks and had ≥1 Hb value available at week 4 or later. 
The estimated difference in Hb level between the groups was determined by analysis of 
covariance (ANCOVA). Treatment was included as a factor and the covariates were mean 
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baseline Hb and mean weekly dose during the evaluation period. HX575 would be 
considered equivalent to the reference medicine if the two-sided 90% confidence intervals 
(CI) resided entirely within the equivalence limits of -0.5 g/dL to 0.5 g/dL. It was planned to 
randomize at least 360 patients to maintain at least 320 evaluable patients (randomized 1:1 
to HX575 and the reference medicine) to have 90% power to reject the null hypothesis that 
the treatment with HX575 was not equivalent to the reference medicine. 
Secondary endpoints included the incidence of antibody formation against epoetin (anti-
erythropoietin binding antibodies and neutralizing antibodies), overall safety profiles, and 
epoetin dose. The safety population consisted of all patients who were randomized and 
received ≥1 dose of study drug. The evaluation of the immune response was based on a 
validated, highly sensitive anti-erythropoietin antibody-binding radioimmunoprecipitation 
(RIP) assay and validated cell-based neutralizing antibody assays performed at the sponsor’s 
laboratory. 
 
RESULTS 
A total of 835 patients were screened, of whom 437 were randomized (Supplemental 
material, Figure S1). Two patients were treated but excluded from any analyses due to 
informed consent issues; the remaining 435 comprised the safety population. In total, 210 
patients treated with HX575 and 212 patients treated with the reference medicine were 
included in the ITT population and were analyzed for the primary endpoint. 
Baseline demographic and clinical characteristics were similar between the treatment 
groups (Table 1). Overall, mean (standard deviation [SD]) age was 58.7 (13.6) years and 
57.5% of patients were male. The primary cause of CKD was diabetes (HX575, 53.0%; 
reference medicine, 56.0%), followed by hypertension (HX575, 30.0%; reference medicine, 
23.9%) and chronic glomerulonephritis (HX575, 6.0%; reference medicine, 7.3%). 
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Efficacy 
At baseline, mean (SD) Hb concentration was 10.53 (0.64) g/dL in the HX575 group and 
10.50 (0.62) g/dL in the reference medicine group (Table 2). Hb values at the end of the 
evaluation period and the Hb change from baseline to evaluation period were similar 
between treatment groups (Table 2 and Figure 1). The estimated difference between groups 
in mean absolute change in Hb concentration was -0.093 g/dL, with 90% CI (-0.23, 0.04) 
entirely within the pre-specified equivalence limits (-0.5, 0.5 g/dL), therefore the primary 
endpoint of the study was met.  
Epoetin dose 
The mean (SD) epoetin dose in the HX575 group was 7761 (9488) IU at week 1, 5877 (5786) 
IU during the evaluation period (week 21–28), and 6054 (8381) IU at week 52. For the 
reference group, the mean (SD) epoetin dose was 6662 (6447) IU at week 1, 5840 (6065) IU 
during the evaluation period (week 21–28), and 4440 (5315) IU at week 52. The mean 
weekly epoetin dose tended to be higher in the HX575 group than in the reference group; 
this difference was present at the beginning of the study (i.e. after conversion from the pre-
study ESA treatment) and the trend continued throughout the study. 
Safety 
The most frequently reported TEAEs were hypertension (HX575, 11.5%; reference medicine 
13.3%), diarrhea (HX575, 10.1%; reference medicine, 8.7%), hyperkalemia (both groups, 
9.2%), and nausea (HX575, 7.8%; reference medicine, 9.6%). In total, 5 (2.3%) patients in the 
HX575 group and 11 (5.0%) in the reference group reported TEAEs considered by 
investigators to be related to the study drug (Supplemental material, Table S1). 
Four (0.9%) patients experienced five treatment-emergent serious AEs (SAEs) that were 
considered related to treatment. In the HX575 group, three (1.4%) patients experienced 
four related treatment-emergent SAEs (cerebrovascular accident, ischemic stroke, 
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myocardial infarction, and worsening of anemia), while in the reference group, there was 
one (0.5%) case of congestive cardiac failure considered related to treatment. 
Thromboembolic events and de-novo malignancies were categorized as TEAEs of special 
interest. The incidence of thromboembolic events was similar between the two treatment 
groups (HX575, 35 [16.1%] patients and 45 events; reference medicine, 36 [16.5%] patients 
and 54 events). Malignancies were reported more frequently for the reference medicine 
group (9 patients [4.1%] versus 4 patients (1.8%) in the HX575 treatment group), however, 
the absolute number of events was very low in general (10 versus 4 events, respectively). 
Five patients in the HX575 group and 11 in the reference medicine group died during the 
treatment phase (up to 30 days after last dose) due to TEAEs. In both treatment groups, the 
most common TEAEs leading to death were conditions associated with the System Organ 
Class Cardiac Disorders (n=5 in each group). The other TEAEs leading to death in the 
reference medicine group where chronic renal failure, azotemia, 
endocarditis/cerebrovascular accident, bladder cancer, acute respiratory failure and 
cachexia (all n=1). No causal relationship with the study drug was suspected in any of the 
TEAEs leading to death.  
Immunogenicity 
Nine patients tested positive for binding anti-erythropoietin antibodies by RIP assay (Table 
3; 7 patients in the HX575 group and 2 in the reference group). This includes two patients 
(one patient from each treatment arm) who were already RIP-positive at baseline, prior to 
which all patients had been receiving pre-study treatment with the reference medicine. 
Both of these patients tested negative at the first screening assessment but positive at the 
baseline assessment (sample taken before any administration of study drug), and were 
discontinued (as per protocol) when the results of the baseline assessment became 
available. Treatment-emergent binding anti-erythropoietin antibodies were detected in 7 
patients (6 [2.8%] in the HX575 group and 1 [0.5%] in the reference group); treatment 
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duration-related incidence rates of anti-erythropoietin antibodies were 0.036 (HX575) and 
0.011 (reference medicine; Table 4). The titers of RIP anti-erythropoietin antibodies were 
low and fluctuating, and all 7 patients who tested positive in the RIP assay at one point 
during the study had at least one subsequent negative RIP assay result. None of these 
patients developed neutralizing anti-erythropoietin antibodies at any time. 
The occurrence of binding but non-neutralizing anti-erythropoietin antibodies was not 
found to be associated with AEs during the study period and for 30 days following study 
discontinuation, nor to have any impact on efficacy in the study period and the subsequent 
safety follow-up. There were no clinical signs of immunogenicity or hypersensitivity during 
the 12-month treatment period. 
 
DISCUSSION 
The double-blind, comparative ACCESS study met its primary objective and demonstrated 
that SC administration of HX575 in patients on dialysis with renal anemia was 
therapeutically equivalent to the reference medicine administered SC in terms of 
maintaining stable Hb levels. In addition to comparable efficacy, HX575 and the reference 
medicine demonstrated a similar safety profile, which was also consistent with that 
expected for epoetin alfa in patients on dialysis. Furthermore, SC administration of HX575 or 
the reference medicine did not elicit the development of neutralizing or otherwise clinically 
relevant antibodies during the 12-month study period and during the subsequent safety 
follow-up (at least 6 months).  
These findings are consistent with those from an open-label single-arm, phase III European 
study, which found that SC HX575 maintained stable Hb levels in 416 dialysis- and non-
dialysis-dependent adult patients with CKD [Casadevall et al 2017]. Also in the European 
study, no patient developed neutralizing antibodies and anti-erythropoietin antibodies were 
mainly transient despite the fact that all patients who tested positive for anti-drug 
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antibodies remained in the study and continued treatment with SC HX575. In contrast, 
patients in the ACCESS study were discontinued if they tested positive in the RIP assay, in 
accordance with the study protocol.  
The proportion of patients in ACCESS who tested positive for anti-erythropoietin antibodies 
after study drug administration is similar to that in the European SENSE study [Casadevall et 
al 2017]; it is also consistent with other data from the literature on the development of 
binding, non-neutralizing antibodies following ESA treatment in clinical studies [Barger et al 
2012]. In ACCESS, the titers of RIP anti-erythropoietin antibodies were low and fluctuating. 
All 7 patients who tested positive in the RIP assay at one point during the study had at least 
one subsequent negative RIP assay result, and some patients alternated between positive 
and negative RIP assay results. These observations, together with the highly sensitive RIP 
assay used (a potential 1% false-positive rate), indicate that there was no sustained, 
clinically relevant anti-drug antibody response in any patient. 
An earlier comparative renal anemia study of SC HX575 using pre-filled syringes ended 
prematurely following the occurrence of two cases of neutralizing antibodies [Haag-Weber 
et al 2012]. A thorough root-cause analysis identified aggregate formation due to increased 
tungsten levels [Seidl et al 2012]; the source of these elevated tungsten levels was the heat-
resistant tungsten pins used to manufacture the glass syringes. A switch to special low-
tungsten syringes eliminated this risk and reduced the immune potential of HX575, as 
evidenced in the SENSE study [Casadevall et al 2017]. In the ACCESS study, medication was 
provided in single-dose vials (consistent with the US-approved reference medicine) and had 
never been in contact with tungsten. 
In the current ACCESS study, patients randomized to HX575 received a slightly higher 
starting dose than those randomized to the reference medicine, and this trend continued 
throughout the study treatment period. The double-blind nature of the study treatment 
excludes the role of investigator bias in administering higher doses in the HX575 arm from 
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the start. The higher doses of HX575 throughout the study treatment period are unlikely to 
be due to decreased effectiveness compared with the reference medicine, given that the 
dose difference was evident from the start of treatment. There is also no evidence of a dose 
penalty when switching to biosimilar ESAs, based on other published data. A large (n=1695 
patients with CKD) post-approval study of HX575 administered IV was conducted to monitor 
AEs in clinical practice, and also assessed the efficacy of HX575 after conversion from a 
range of pre-study ESAs [Hörl et al 2012]. Target Hb levels were maintained effectively after 
patients were switched to IV HX575. The dose of HX575 was stable in those patients 
switched from previous IV ESA treatment, with a significant (but expected) 13% dose 
increase in patients switched from prior SC ESA treatment. Another study investigated 
differences between originator and biosimilar ESA utilization based on defined daily doses 
(DDD), doses upon switching, differences between short- and long-acting ESAs and 
prescribed daily doses (PDD) in ambulatory patients (n=6117) with renal anemia undergoing 
chronic maintenance hemodialysis [Hörbrand et al 2013]. In this population-based analysis 
of real-world data, doses were not increased when the therapy was switched from the 
originator to the biosimilar ESA. Moreover, in 1,886 patients receiving a continuous 
prescription over 12 accounting quarters, patients receiving short-acting originator ESAs, 
long-acting darbepoetin alfa and biosimilar ESAs had a similar median daily DDD 
consumption (0.80, 0.86 and 0.81, respectively) [Hörbrand et al 2013]. 
In summary, SC administration of HX575 in patients on dialysis with renal anemia was 
therapeutically equivalent to the reference medicine in terms of maintaining stable Hb 
levels. SC administration of HX575 and the reference medicine was well tolerated, and the 
safety profile of each was similar and as expected in patients on dialysis. SC administration 
of HX575 and the reference medicine did not elicit the development of neutralizing, 
clinically relevant antibodies during the 12-month study period and the 6-month safety 
follow-up period.  
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Table 1. Patient demographics and baseline characteristics (safety population) 
 
Parameter   HX575 
N=217 
Reference 
epoetin alfa 
N=218 
Age, years mean (SD)  59.8 (13.76) 57.6 (13.40) 
 min, max  23, 90 24, 89 
Sex, n (%)  Male 135 (62.2) 115 (52.8) 
 Female  82 (37.8) 103 (47.2) 
Race, n (%) Caucasian  139 (64.1) 128 (58.7) 
 Black or African American 57 (26.3) 72 (33.0) 
 Asian 6 (2.8) 13 (6.0) 
 Other* 15 (6.9) 5 (2.3) 
Height, cm  mean (SD) 167.2 (10.17) 166.0 (10.33) 
 min, max  132, 201 142, 203 
Weight, kg  mean (SD)  82.8 (20.75) 86.5 (24.32) 
 min, max  41, 146 44, 178 
BMI, kg/m2 mean (SD)  29.55 (6.872) 31.41 (8.783) 
 min, max  17.6, 49.1 16.9, 69.9 
Time since start of 
dialysis, months 
mean (SD) 51.14 (49.93) 55.62 (60.14) 
Method of dialysis at 
baseline, n (%) 
Hemodialysis 192 (88.5) 192 (88.1) 
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 Peritoneal dialysis 25 (11.5) 26 (11.9) 
Time since start of 
ESA therapy, months 
mean (SD) 40.72 (38.22) 48.38 (50.59) 
Receiving iron 
therapy**, n (%) 
 72 (33.2) 70 (32.1) 
*other race includes “American Indian or Alaska native”, “Native Hawaiian or other Pacific Islander” 
**prior to first administration of study drug 
BMI = body mass index, ESA = erythropoiesis-stimulating agent, SD = standard deviation 
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Table 2. Hemoglobin levels (ITT population) 
 
  Hb level, g/dL   
Treatment 
group 
Time point Mean SD min, max LS Mean SE 
HX575 
N=210 
Baseline period 10.53 0.635 8.4, 12.5   
Evaluation period 10.42 0.826 7.1, 12.8   
Change from 
baseline to 
evaluation period 
-0.11 1.001 -3.1, 2.8 -0.0960 0.0575 
Reference 
epoetin 
alfa 
N=212 
Baseline period 10.50 0.615 8.3, 11.8   
Evaluation period 10.51 0.873 7.8, 12.5   
Change from 
baseline to 
evaluation period 
0.01 0.953 -2.8, 2.5 -0.0035 0.0573 
Hb=hemoglobin; ITT=intention-to-treat; LS=least squares; SD=standard deviation; SE=standard error 
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Table 3. Incidence of antibody formation against erythropoietin during the treatment period 
(safety population) 
 
Treatment 
group 
Assay Patients 
with any result, 
n 
Patients with 
a positive 
result, n 
Percent 
(95% CI) 
Incidence rate 
related to treatment 
duration 
HX575 
N=217 
RIP 214 7 3.3 (1.3, 6.6) 0.036 
NAb 7 0 - - 
Reference 
epoetin alfa 
N=218 
RIP 216 2 0.9 (0.1, 3.3) 0.011 
NAb 2 0 - - 
CI=confidence interval; NAb=neutralizing antibody; RIP=radioimmunoprecipitation 
Two patients (1 in each group) were already RIP-positive at baseline prior to study treatment 
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Figure 1. Mean (SD) Hb levels over time (ITT population) 
 
 
Hb=hemoglobin; ITT=intention-to-treat; SD=standard deviation 
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Supplemental material 
Figure S1. Patient disposition 
 
  
  
835 patients screened
437 patients randomized
Screen failures, n=398
Did not meet eligibility criteria, n=330
Other, n=68
217 patients
received  
HX575
218 patients 
received 
reference medicine
173 patients completed
Did not complete, n=44
Withdrew consent, n=15
Kidney transplantation, n=7
Binding anti-epoetin 
antibodies, n=6
Deviation from treatment 
regimen, n=6
Change in dialysis
modality, n=2
Adverse event, n=1
Death, n=5
Non-compliance, n=2
161 patients completed
Did not complete, n=57
Withdrew consent, n=22
Kidney transplantation, n=7
Binding anti-epoetin antibodies, n=2
Deviation from treatment 
regimen, n=6
Change in dialysis
modality, n=1
Other protocol
deviations, n=1
Investigator’s decision, n=2
Lost to follow-up, n=1
Adverse event, n=6
Death, n=8
Non-compliance, n=1
Excluded due to informed consent issues, 
n=2
435 patients analyzed
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Table S1. Overview of treatment-emergent adverse events (safety population) 
 
 HX575 
N=217 
n (%) E 
Reference epoetin alfa 
N=218 
n (%) E 
TEAE 178 (82.0) 1078 185 (84.9) 1347 
Drug-related  5 (2.3) 6 11 (5.0) 12 
Serious  91 (41.9) 211 90 (41.3) 265 
Drug-related serious  3 (1.4) 4 1 (0.5) 1 
Special interest events 39 (18.0) 49 44 (20.2) 64 
Thromboembolic events 35 (16.1) 45 36 (16.5) 54 
Malignancies 4 (1.8) 4 9 (4.1) 10 
Study-drug discontinuation 5 (2.3) 5 14 (6.4) 14 
Death 5 (2.3) 5 11 (5.0) 12 
E=number of events; n=number of patients; TEAE=treatment-emergent adverse event 
 
